Immune checkpoint inhibitors

Immunology-based therapy is rapidly developing into an effective treatment option for a surprising range of cancers. We have learned over the last decade that powerful immunologic effector cells may be blocked by inhibitory regulatory pathways controlled by specific molecules often called "immune checkpoints." The development of a new therapeutic class of drugs that inhibit these inhibitory pathways has recently emerged as a potent strategy in oncology. Three sets of agents have emerged in clinical trials exploiting this strategy. These agents are antibody-based therapies targeting cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1). These inhibitors of immune inhibition have demonstrated extensive activity as single agents and in combinations. Clinical responses have been seen in melanoma, renal cell carcinoma, small cell lung cancer, and several other tumor types.

 One of the most exciting aspects of checkpoint inhibition in cancer therapy is that, unlike conventional cytotoxic drugs and targeted agents, it has the potential to work universally in all cancers. Checkpoint inhibitors, alone or in combination, have yielded promising results not only in advanced melanoma and RCC but also in triple-negative breast cancer and cancers of the prostate, bladder, lung, and head and neck.

  • Drugs
  • Recognision of immune cells
  • Attacking mechanisms
  • Adverse effects of these drugs
  • Considerations in Using/Prescribing
  • PD-1 or PD-L1 Targetors/Targets
  • Targetting CTLA-4

Related Conference of Immune checkpoint inhibitors

April 19-20, 2018

7th World Congress on Immunology

Amsterdam, Netherlands
May 16-17, 2018

World Congress on Allergy and Immunotherapy

Osaka, Japan
September 13-14, 2018

World Conference on Vaccine and Immunology

Bucharest, Romania
September 13-14, 2018

11th Annual Congress on Immunology & Immunotechnology

Zurich, Switzerland
September 17-18, 2018

3rd International Conference on Tumor & Cancer Immunology and Immunotherapy

San Diego, California, USA
September 17-18, 2018

3rd International Conference on Tumor & Cancer Immunology and Immunotherapy

San Diego, California, USA
September 20-21, 2018

Global Meet on Immunology and Molecular Biology

Oslo, Norway
October 19-20, 2018

10th World Congress and Expo on Immunology

New York, USA
October 29-30, 2018

6th International Conference on HIV/AIDS, STDs and STIs

San Francisco, USA
November 26-27, 2018

3rd International Conference on Autoimmunity

Dublin, Ireland
December 05-06, 2018

4th Antibodies, Antibiotics and Bio Therapeutics Congress

Chicago, Illinois, USA
March 04-05, 2019

10th Molecular Immunology & Immunogenetics Congress

Barcelona, Spain

Immune checkpoint inhibitors Conference Speakers

Recommended Sessions

Related Journals

Are you interested in